PBYI · Puma Biotechnology, Inc.
$8.12
+0.13 (+1.63%)
At close · Aug 6
Market Cap
$413.30M
Shares
50.90M
Puma Biotechnology, Inc. Earnings Call Transcripts
Every quarterly earnings call for Puma Biotechnology, Inc. (PBYI) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲23.5%
$57.10M
−$360,000
'22 Q3
22-11-03
▲5.9%
$58.64M
−$10.41M
'22 Q4
23-03-02
▼8.3%
$54.57M
$2.13M
'23 Q2
23-08-03
▼1.7%
$56.12M
$5.80M
'23 Q3
23-11-02
·
$43.77M
−$4.82M
'24 Q1
24-05-02
▼13.7%
$47.08M
−$4.53M
'24 Q2
24-08-01
▲43.5%
$80.54M
$20.32M
'24 Q3
24-11-07
·
$59.08M
$19.30M
'24 Q4
25-02-27
▲5.1%
$46.01M
$2.97M
'25 Q1
25-05-08
▲11.4%
$52.44M
$5.86M
'25 Q2
25-08-07
▼32.4%
$54.48M
$8.84M
'25 Q3
25-11-06
▲27.7%
$75.45M
$13.44M
'25 Q4
26-02-26
LATEST
▼2.6%
$44.81M
−$3.75M
'26 Q1
26-05-07
Earnings call
FY26 · Q2
2026-08-06
August 6, 2026 - Puma Biotechnology 2Q-2026 Financial Results Conference Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Puma Biotechnology, Inc. Q1 FY2026 Earnings Call
Positive tone
Alisca Lung-1 Phase II trial
Unmet medical need / company mission
Dose escalation
Revenue
$44.81M
▼ 2.6% YoY Diluted EPS
$-0.07
▼ 216.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Puma Biotechnology, Inc. Q4 FY2025 Earnings Call
Positive tone
NERLYNX Commercial Performance
ALISCA-Lung1 Trial
ALISCA-Breast1 Trial
Revenue
$75.45M*
▲ 27.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Puma Biotechnology, Inc. Q3 FY2025 Earnings Call
Positive tone
NERLYNX commercial performance
Alisertib ALISCA-Breast1 trial
Regulatory and development path for alisertib
Revenue
$54.48M
▼ 32.4% YoY Diluted EPS
$0.17
▼ 58.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Puma Biotechnology, Inc. Q2 FY2025 Earnings Call
Positive tone
ALISCA-Breast Phase II trial
NERLYNX commercial performance
ALISCA-Lung1 Phase II trial
Revenue
$52.44M
▲ 11.4% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Puma Biotechnology, Inc. Q1 FY2025 Earnings Call
Positive tone
NERLYNX commercial performance
Alisertib clinical development
Neratinib combination data with Enhertu
Revenue
$46.01M
▲ 5.1% YoY Diluted EPS
$0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Puma Biotechnology, Inc. Q4 FY2024 Earnings Call
Revenue
$59.08M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Puma Biotechnology, Inc. Q3 FY2024 Earnings Call
Positive tone
Alisertib safety / tolerability profile
Royalty revenue from China/Pierre Fabre
NERLYNX commercial performance
Revenue
$80.54M
▲ 43.5% YoY Diluted EPS
$0.41
▲ 241.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Puma Biotechnology, Inc. Q2 FY2024 Earnings Call
Positive tone
Alisertib clinical development
NERLYNX commercial performance
Royalty revenue and China dynamics
Revenue
$47.08M
▼ 13.7% YoY Diluted EPS
$-0.09
▼ 280% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Puma Biotechnology, Inc. Q1 FY2024 Earnings Call
Balanced tone
Alisertib clinical pipeline
NERLYNX product revenue decline
Sales force and HCP engagement
Revenue
$43.77M
Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Puma Biotechnology, Inc. Q4 FY2023 Earnings Call
Positive tone
Alisertib Pipeline Development
NERLYNX Commercial Performance
Business Development and In-Licensing
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Puma Biotechnology, Inc. Q3 FY2023 Earnings Call
Revenue
$56.12M
▼ 1.7% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Puma Biotechnology, Inc. Q2 FY2023 Earnings Call
Revenue
$54.57M
▼ 8.3% YoY Diluted EPS
$0.05
▼ 76.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Puma Biotechnology, Inc. Q1 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Puma Biotechnology, Inc. Q4 FY2022 Earnings Call
Revenue
$58.64M*
▲ 5.9% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Puma Biotechnology, Inc. Q3 FY2022 Earnings Call
Revenue
$57.10M
▲ 23.5% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Puma Biotechnology, Inc. Q2 FY2022 Earnings Call
Revenue
$59.52M
▲ 11.5% YoY Diluted EPS
$0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Puma Biotechnology, Inc. Q1 FY2022 Earnings Call
Revenue
$52.77M
▼ 46.2% YoY Diluted EPS
$0.03
▼ 92.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Puma Biotechnology, Inc. Q4 FY2021 Earnings Call
Revenue
$55.36M*
▲ 5.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Puma Biotechnology, Inc. Q3 FY2021 Earnings Call
Revenue
$46.24M
▼ 8.9% YoY Diluted EPS
$-1.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Puma Biotechnology, Inc. Q2 FY2021 Earnings Call
Revenue
$53.38M
▼ 24.4% YoY Diluted EPS
$-0.13
▼ 262.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Puma Biotechnology, Inc. Q1 FY2021 Earnings Call
Revenue
$98.17M
▲ 91.7% YoY Diluted EPS
$0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Puma Biotechnology, Inc. Q4 FY2020 Earnings Call
Revenue
$52.56M
▼ 16.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Puma Biotechnology, Inc. Q3 FY2020 Earnings Call
Revenue
$50.75M
▼ 9.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Puma Biotechnology, Inc. Q2 FY2020 Earnings Call
Revenue
$70.58M
▲ 30.9% YoY Diluted EPS
$0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Puma Biotechnology, Inc. Q1 FY2020 Earnings Call
Revenue
$51.22M
▼ 48.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Puma Biotechnology, Inc. Q4 FY2019 Earnings Call
Revenue
$62.92M
▼ 11.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1401667
CUSIP
74587V107
13F (30d)
40 filings
40 filers
Visit website
Investor relations